BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 33916178)

  • 1. Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions.
    Karunakaran KB; Yanamala N; Boyce G; Becich MJ; Ganapathiraju MK
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
    Vavougios GD; Solenov EI; Hatzoglou C; Baturina GS; Katkova LE; Molyvdas PA; Gourgoulianis KI; Zarogiannis SG
    Am J Physiol Lung Cell Mol Physiol; 2015 Oct; 309(7):L677-86. PubMed ID: 26254420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genes and Pathways Involved in the Progression of Malignant Pleural Mesothelioma: A Meta-analysis of Genome-Wide Expression Studies.
    Mejia-Garcia A; Bonilla DA; Ramirez CM; Escobar-Díaz FA; Combita AL; Forero DA; Orozco C
    Biochem Genet; 2024 Feb; 62(1):352-370. PubMed ID: 37347449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic significance and immune cell infiltration analysis of differentially expressed genes in malignant pleural mesothelioma].
    Wang N; Zhao QN; Yuan Q; Zhu BL; Wu W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Sep; 41(9):641-647. PubMed ID: 37805421
    [No Abstract]   [Full Text] [Related]  

  • 6. Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status.
    Rouka E; Vavougios GD; Solenov EI; Gourgoulianis KI; Hatzoglou C; Zarogiannis SG
    Front Physiol; 2017; 8():156. PubMed ID: 28377727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
    Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis.
    Zhang X; Yang L; Chen W; Kong M
    Oncol Res Treat; 2020; 43(12):656-671. PubMed ID: 33032291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.
    Rouka E; Beltsios E; Goundaroulis D; Vavougios GD; Solenov EI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212858
    [No Abstract]   [Full Text] [Related]  

  • 11. UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    Reardon ES; Shukla V; Xi S; Gara SK; Liu Y; Straughan D; Zhang M; Hong JA; Payabyab EC; Kumari A; Richards WG; De Rienzo A; Hassan R; Miettinen M; Xi L; Raffeld M; Uechi LT; Li X; Wang R; Chen H; Hoang CD; Bueno R; Schrump DS
    J Thorac Oncol; 2021 Jan; 16(1):89-103. PubMed ID: 32927122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
    Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
    Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.
    Xiao Y; Huang W; Zhang L; Wang H
    Front Endocrinol (Lausanne); 2022; 13():1056152. PubMed ID: 36523602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).
    Wright CM; Kirschner MB; Cheng YY; O'Byrne KJ; Gray SG; Schelch K; Hoda MA; Klebe S; McCaughan B; van Zandwijk N; Reid G
    PLoS One; 2013; 8(8):e70940. PubMed ID: 23976967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma.
    Digifico E; Erreni M; Mannarino L; Marchini S; Ummarino A; Anfray C; Bertola L; Recordati C; Pistillo D; Roncalli M; Bossi P; Zucali PA; D'Incalci M; Belgiovine C; Allavena P
    Front Immunol; 2023; 14():1116430. PubMed ID: 37398648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
    Tian K; Bakker E; Hussain M; Guazzelli A; Alhebshi H; Meysami P; Demonacos C; Schwartz JM; Mutti L; Krstic-Demonacos M
    J Transl Med; 2018 Oct; 16(1):282. PubMed ID: 30316293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
    Dong L; Jensen RV; De Rienzo A; Gordon GJ; Xu Y; Sugarbaker DJ; Bueno R
    BMC Med Genet; 2009 Dec; 10():149. PubMed ID: 20043850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of CD24 gene in human malignant pleural mesothelioma and its relationship with prognosis].
    Li B; Zhou CX; Pu YQ; Qiu L; Mei W; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Mar; 41(3):168-176. PubMed ID: 37006141
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of genes and pathways involved in malignant pleural mesothelioma using bioinformatics methods.
    Liu X; Qian K; Lu G; Chen P; Zhang Y
    BMC Med Genomics; 2021 Apr; 14(1):104. PubMed ID: 33849532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.